Individual mammalian cells contain billions of protein molecules, which must be synthesized, deployed, and removed with ...

Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted therapies. This story was originally published on BioPharma Dive. To receive ...

Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems to eliminate disease-causing proteins. Innovators are making rapid and ...

Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at ...

Proteins that are no longer needed, defective, or potentially harmful are labeled with a molecular "tag" and dismantled in ...

Targeted protein degradation is a therapeutic strategy that utilizes the cell’s natural machinery to eliminate disease-causing proteins. The field traces its origins to the development of thalidomide ...

Argobio Studio, the launch platform for Europe's best innovative science, today announced the successful seed financing of Enodia Therapeutics, a ...

Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS' Leadership in Innovative Cancer Therapies The latest data presented for the three lead CELMoD agents and BCL6 LDD ...

A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...